← Open Payments lookup

NPI 1992874077: Open Payments

NPI 1992874077. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$947 in 14 payments from 7 companies in 2025. Trend: 2023 $6,045 · 2024 $3,715 · 2025 $947

Food & beverage: $947
CompanyPaymentsAmount
Alkermes, Inc.5$214
Otsuka America Pharmaceutical, Inc.3$156
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)1$125
IDORSIA PHARMACEUTICALS US INC1$121
ABBVIE INC.2$117
Axsome Therapeutics, Inc.1$107
Teva Pharmaceuticals USA, Inc.1$107

Products named: CAPLYTA, LYBALVI, REXULTI, QUVIVIQ, VRAYLAR, Auvelity, AUSTEDO XR, ARISTADA.